Compare AMWL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMWL | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 92.6M |
| IPO Year | 2020 | 2017 |
| Metric | AMWL | RFL |
|---|---|---|
| Price | $10.98 | $2.10 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | 151.3K | ★ 245.4K |
| Earning Date | 05-05-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.06 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $3.71 | $1.12 |
| 52 Week High | $13.45 | $3.96 |
| Indicator | AMWL | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 43.37 |
| Support Level | $4.49 | $1.21 |
| Resistance Level | N/A | $3.96 |
| Average True Range (ATR) | 0.92 | 0.26 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 48.54 | 16.00 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.